海外拓展是今年重要的业务目标。本文为IPO早知道原创作者|罗宾据IPO早知道消息,4月24日,荃信生物(2509.HK)宣布与Caldera Therapeutics(下称“Caldera”)就公司自主研发的临床前阶段长效自免双抗QX030N签订授权许可协议,授予Caldera开发及商业化QX030N的全球独家许可。根据协议,Caldera获授予研究、开发、注册、生产及商业化QX030N的全球独家...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.